Iterum Therapeutics plc (ITRMF) Cash from Investing Activities (2017 - 2025)

Iterum Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$12000.0 for Q3 2025.

• In Q3 2025, Cash from Investing Activities fell 100.21% year-over-year to -$12000.0; the TTM figure through Sep 2025 stood at $1.1 million (down 96.45% YoY), while the FY2024 annual figure was $18.2 million, down 21.97% from the prior year.
• Cash from Investing Activities for Q3 2025 stood at -$12000.0, down from -$2000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $13.5 million in Q4 2023, with the low at -$33.9 million in Q1 2021.
• The 5-year median for Cash from Investing Activities is $3.8 million (2022), against an average of $49555.6.
• The sharpest annual moves came in 2021 and 2025: Cash from Investing Activities jumped 54933.33% in 2021, then sank 100.21% in 2025.
• Iterum Therapeutics' Cash from Investing Activities stood at -$4.5 million in 2021, then surged by 198.03% to $4.4 million in 2022, then soared by 208.89% to $13.5 million in 2023, then sank by 91.87% to $1.1 million in 2024, then slumped by 101.09% to -$12000.0 in 2025.
• Business Quant data shows ITRMF's Cash from Investing Activities at -$12000.0 in Q3 2025, -$2000.0 in Q1 2025, and $1.1 million in Q4 2024.